ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
LC3B Mediated SETDB1-Accounted Alcoholic Steatohepatitis via Lipidation-Dependent LAP and Lipidation-Independent Nuclear Stabilization.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Alcohol-associated liver disease (ALD) progresses from steatosis to steatohepatitis, but the underlying mechanisms remain unclear. Here, we investigated SETDB1's role in ALD progression involving LC3B-mediated LC3-associated phagocytosis (LAP). SETDB1 expression was progressively downregulated in livers of alcohol-fed mice and ethanol-treated hepatocytes, correlating with disease severity. Setdb1 HKO mice exhibited accelerated ALD progression, developing severe steatosis, inflammation, and fibrosis even under pair-fed conditions, indicating SETDB1 deficiency enhances disease susceptibility to nutritional stressors. Mechanistically, SETDB1 acted as a transcriptional cofactor for ERG to promote Map1lc3b transcription. SETDB1 deficiency impaired LAP by disrupting Rubicon membrane localization, causing defective lipid droplet clearance and enhanced cGAS-STING activation. The ATG16L1 WD40 domain was essential for this LAP-mediated protection. LC3B restoration in Setdb1 HKO mice ameliorated steatosis, inflammation, and liver injury. Notably, the lipidation-deficient LC3B-G120A mutant failed to rescue steatosis but partially suppressed inflammation, revealing a lipidation-independent LC3B function. We demonstrate lipidated LC3B mediates cytoplasmic LAP-dependent lipid clearance, while non-lipidated LC3B translocates to the nucleus, reducing R-loop accumulation, preserving genomic stability, and restraining cGAS-STING-driven inflammation. Collectively, these findings define a protective SETDB1-ERG-LC3B axis restraining ALD progression and reveal dual LC3B functions, offering mechanistic insight and a potential therapeutic strategy for intercepting steatosis-to-steatohepatitis transition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.